Literature DB >> 18617641

Portopulmonary hypertension: survival and prognostic factors.

Jérôme Le Pavec1, Rogério Souza, Philippe Herve, Didier Lebrec, Laurent Savale, Colas Tcherakian, Xavier Jaïs, Azzedine Yaïci, Marc Humbert, Gérald Simonneau, Olivier Sitbon.   

Abstract

RATIONALE: Portopulmonary hypertension (PoPH) can be defined as elevation of pulmonary arterial pressure and pulmonary vascular resistance in the setting of portal hypertension. Survival results in PoPH are contrasting, and prognostic factors need to be identified.
OBJECTIVES: To analyze long-term survival in a large cohort of patients with PoPH with the aim of determining the independent variables affecting survival.
METHODS: We retrospectively analyzed charts of all patients referred to the French Referral Center for pulmonary arterial hypertension with the diagnosis of PoPH between 1984 and 2004.
MEASUREMENTS AND MAIN RESULTS: The study population comprised 154 patients; 57% male. Mean age at diagnosis was 49 +/- 11 years, 60% of patients were in New York Heart Association functional class III-IV, and mean 6-minute walk distance was 326 +/- 116 m. Hemodynamic measurements showed a mean pulmonary arterial pressure of 53 +/- 13 mm Hg, cardiac index of 2.9 +/- 0.9 L/min/m(2), and pulmonary vascular resistance of 752 +/- 377 dyn/s/cm(5). Portal hypertension was related to cirrhosis in 136 patients, with a severity assessed as follows: Child-Pugh class A 51%, Child-Pugh class B 38%, Child-Pugh class C 11%. Overall survival rates at 1, 3, and 5 yr were 88, 75, and 68%, respectively. Multivariate regression analysis individualized the presence and severity of cirrhosis and cardiac index as major independent prognostic factors.
CONCLUSIONS: Prognosis in PoPH is mainly related to the presence and severity of cirrhosis and to cardiac function. The place of pulmonary arterial hypertension-specific therapies remains to be determined in the setting of PoPH.

Entities:  

Mesh:

Year:  2008        PMID: 18617641     DOI: 10.1164/rccm.200804-613OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  41 in total

1.  Pulmonary complications of cirrhosis.

Authors:  Rajan Kochar; Moises I Nevah Rubin; Michael B Fallon
Journal:  Curr Gastroenterol Rep       Date:  2011-02

2.  Portopulmonary hypertension: challenges in diagnosis and management.

Authors:  Patrick J Troy; Aaron B Waxman
Journal:  Therap Adv Gastroenterol       Date:  2009-09       Impact factor: 4.409

3.  Portopulmonary hypertension.

Authors:  Ravi P Nayak; Dechun Li; George M Matuschak
Journal:  Curr Gastroenterol Rep       Date:  2009-02

Review 4.  Epidemiology of pulmonary arterial hypertension.

Authors:  Xin Jiang; Zhi-Cheng Jing
Journal:  Curr Hypertens Rep       Date:  2013-12       Impact factor: 5.369

Review 5.  [Pulmonary complications in liver diseases].

Authors:  T Horvatits; A Drolz; K Rutter; S Kluge; V Fuhrmann
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-04-26       Impact factor: 0.840

6.  Effectiveness of phosphodiesterase-5 inhibitor therapy for portopulmonary hypertension.

Authors:  Jolene H Fisher; Sindhu R Johnson; Cathy Chau; Amie T Kron; John T Granton
Journal:  Can Respir J       Date:  2014-12-18       Impact factor: 2.409

Review 7.  [Hepatocardiac disorders : Interactions between two organ systems].

Authors:  T Horvatits; A Drolz; K Rutter; K Roedl; S Kluge; V Fuhrmann
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-06-13       Impact factor: 0.840

Review 8.  [Hepatopulmonary interactions].

Authors:  V Fuhrmann; P Tariparast
Journal:  Med Klin Intensivmed Notfmed       Date:  2018-08-06       Impact factor: 0.840

9.  Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease.

Authors:  Kari E Roberts; Michael B Fallon; Michael J Krowka; Robert S Brown; James F Trotter; Inga Peter; Hocine Tighiouart; James A Knowles; Daniel Rabinowitz; Raymond L Benza; David B Badesch; Darren B Taichman; Evelyn M Horn; Steven Zacks; Neil Kaplowitz; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2009-02-12       Impact factor: 21.405

Review 10.  Pulmonary vascular complications of liver disease.

Authors:  Jason S Fritz; Michael B Fallon; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2012-11-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.